Eli Lilly and Company
•90% Informative
AK-OTOF is a gene therapy being developed for the treatment of sensorineural hearing loss due to mutations in the oto the Association for Research in Otolaryngology 2024 ed frequencies, achieving thresholds of 65 to 20 dB HL, and 30 days the normal hearing range at so AK-OTOF uencies at the D AK 30 visit.
This press release c first ns forward-looking statement AK-OTOF AK-OTOF as a potential treatment for sensorineural hearing loss due to mutations in the otoferlin gene (OTOF) As with any pharmaceutical product, there are substantial risks and uncertainties in the proces AK-OTOF ug research, development, and commercialization. otolar Saturday, February 3 Anaheim Marriott ighLig first t__NxlGi">Joe Fletcher AK-OTOF 11-year-old LightText__NxlGi AK-OTOF Form 10-Q 30 days _hig AK-OTOF ext__NxlGi">Lilly Lilly 65 to 20 Text__NxlGi">Lilly AK-OTOF Lilly AK-OTOF 1995 the Private Securitie over 20 years Reform Act AK ass="summaryFeed_highLightText__NxlGi">LinkedIn AK-OTOF book, Instagram Lilly.com ABR ass="summaryFeed_highLightText__NxlGi">millions 1 _NxlGi">o AK-OTOF n> 4.1E11 maryFeed_highLightText__ Children with OTOF-mediated today nearly 150 years Lilly Lilly Akouos Millions mmaryFeed_highLightText__NxlGi">AK-OTOF one aryFeed_highLightText__NxlGi">Clinical Trial AK AK-OTOF 200,000 Akouos AK-OTOF AAV Clinical Trial first yFeed_highLightText__NxlGi">AK FDA Rare Pediatric Disease Designation Orphan Drug Designa AK-OTOF pan>
VR Score
88
Informative language
88
Neutral language
60
Article tone
formal
Language
English
Language complexity
83
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
10
Affiliate links
no affiliate links